Recent Material Events - La Jolla Pharmaceuticals (LJPC)

Filing Date	Description
2008-08-04	6455 Nancy Ridge Drive, San Diego, California 92121 (Address of principal executive offices) (Zip Code) ...
2008-05-21	On May 16, 2008, Nader J. Naini notified La Jolla Pharmaceutical Company (the “ Company ”) of his resignation from the board of directors of the Company, effective as of the date of the Company’s 2008 annual meeting of stockholders to ...
2008-05-14	Effective May 12, 2008, La Jolla Pharmaceutical Company (the “ Company ”) entered into an amendment (the “ Amendment ”) to its Rights Agreement, dated as of December 3, 1998 and amended on July 21, 2000, December 14, 2005 and Marc ...
2008-05-07	On May 6, 2008, La Jolla Pharmaceutical Company (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with UBS Securities LLC and Canaccord Adams Inc., as representatives of the underwriters (co ...
2008-05-02	6455 Nancy Ridge Drive, San Diego, California 92121 (Address of principal executive offices) (Zip Code) ...
2008-03-04	On March 4, 2008, La Jolla Pharmaceutical Company (the "Company") and Luke Seikkula, Vice President of Manufacturing, entered into an employment agreement (the "Employment Agreement"). The Employment Agreement provided that upon Mr. Seikkula’s ...
2008-02-28	On February 28, 2008, La Jolla Pharmaceutical Company announced and commented on its fourth quarter and year-end financial results for the periods ended December 31, 2007. A copy of the press release is attached hereto as Exhibit 99.1 and incorporate ...
2007-03-20	On March 20, 2007, La Jolla Pharmaceutical Company (the “Company”) issued a press release announcing updated interim antibody data for its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent ® (abetimus sodium)... ...
2007-03-08	On March 8, 2007, La Jolla Pharmaceutical Company (the "Company") issued a press release announcing positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent® (abetimus sodium), its d... ...
2007-03-01	On March 1, 2007, La Jolla Pharmaceutical Company announced and commented on its fourth quarter and year-end financial results for the periods ended December 31, 2006. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by... ...